BETA - What are trispecific antibodies

This video explores trispecific antibodies, one of the newest and most promising advances in cancer immunotherapy, particularly in blood cancers. It begins by explaining the concept of antigens—proteins found on the surface of cells that serve as targets for antibody-based treatments—and builds on this foundation to introduce how trispecific antibodies are designed.

Unlike traditional or even bispecific antibodies, trispecific antibodies can engage three targets at once. Typically, one arm binds to a cancer cell, another to an immune cell (such as a T-cell), and the third either targets an additional marker on the cancer cell to improve precision or enhances the immune response through co-stimulation. This multi-target approach aims to bring immune cells into close contact with cancer cells while strengthening and refining the body’s ability to attack the tumor.

The video explains how trispecific antibodies work by activating immune cells and directing them to kill cancer cells, and why adding a third target may improve both the depth and durability of treatment responses. It also covers how these therapies are administered—either intravenously or subcutaneously—and why step-up dosing is used to gradually introduce the drug and reduce the risk of strong immune reactions.

In addition, the video reviews current research on how trispecific antibodies are being studied, primarily in clinical trials as monotherapies, with emerging interest in combination approaches. It discusses potential side effects, including cytokine release syndrome (CRS), low blood counts, and less common neurological effects like ICANS, noting that many effects depend on the specific targets involved.

Finally, the video highlights key open questions in the field, such as optimal treatment duration, the risk of T-cell exhaustion, and how these therapies will compare to existing options. While trispecific antibodies are not yet approved as of 2026, they represent a significant step forward in precision immunotherapy and may become an important future treatment option for patients with blood cancers.